banner002.jpg
COVID-19 Update | January 15, 2021
Important Highlights
Updated Hospital Reporting Guidance Includes Vaccine Reporting
The Department of Health and Human Services (HHS) on Jan. 12 updated its hospital reporting guidance to include instructions for reporting data on vaccine administration rates for healthcare personnel and patients. The COVID-19 vaccine administration reporting guidance is on pp. 13-14 of the HHS FAQs memo.
 
Reporting these data fields (#41-47) is currently optional. However, recent policy changes to COVID-19 vaccine dose allocation, outlined by HHS Secretary Alex Azar earlier this week, provide an incentive for hospitals to report vaccine administration data. Beginning Jan. 26, HHS “will be allocating [COVID-19 vaccine doses] based on the pace of administration as reported by states and by the size of the 65 and over population in each state.”
 
*UPDATE* CDC Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine 
CDC has released updated clinical guidance related to mRNA vaccines. The updated guidance can be found here: Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19 Vaccine | CDC.  
  • The updated guidance includes:
    • Additional information on antibody therapies and COVID-19 vaccination 
    • Information on COVID-19 vaccination and outbreak management 
    • Additional information on vaccination of immunocompromised persons 
    • Updates to contraindications and precautions to vaccination 
    • Information on COVID-19 vaccination and tuberculin skin testing 
  • Major updates include: 
    • Defining an immediate allergic reaction as “any hypersensitivity-related signs or symptoms such as urticaria, angioedema, respiratory distress (e.g., wheezing, stridor), or anaphylaxis that occur within four hours following administration.” 
    • Identifying contraindications to either of the mRNA COVID-19 vaccines as: 
      • Severe allergic reaction (e.g, anaphylaxis) after a previous dose of an mRNA COVID-19 vaccine or any of its components 
      • Immediate allergic reaction of any severity to a previous dose of an mRNA COVID-19 vaccine or any of its components (including polyethylene glycol [PEG]) 
      • Immediate allergic reaction of any severity to polysorbate (due to potential cross-reactive hypersensitivity with the vaccine ingredient PEG) 
    • Expanding precautions to mRNA COVID-19 vaccines to include not only anaphylaxis but also any previous immediate allergic reaction to any other vaccine or injectable therapy
    • Includes observation periods after vaccination as 30 minutes for any persons with a precaution to vaccination or a history of anaphylaxis due to any cause and 15 minutes for all other persons
Technical Guidance, Standards and Resources
Vaccines
 
MMWRs
 
Infection Prevention and Control
 
Special Settings and Populations
CMS Nursing Home Visitation - COVID-19 (CMS Clinical Standards and Quality/Survey & Certification Group)
 
Frequently Asked Questions (FAQs) on Nursing Home Visitation (CMS Clinical Standards and Quality/Survey & Certification Group)
 
 
Clinical Care
 
Testing and Cases
 
Incident Management
 
Payment and Reimbursement Policy
Information for Patients, Visitors, and the General Public
News Highlights
Hospitals to Report Covid-19 Vaccination Data (Wall Street Journal, Jan. 12)
 
Federal Policy Updates
SHEA Education and Events
 
New this week:
  1. Podcast: COVID-19 Perspectives on the Vaccine Trials & Vaccine Rollout
  2. Town Hall Round 38
    Sunday, January 17, 2021 | 3:00 pm ET
    REGISTER HERE
facebook-2.png twitterlogowhite.png
Click here to unsubscribe.
Powered By Higher Logic

4040 Wilson Blvd, Suite 300, Arlington, VA 22203